Antilipogenic and hypolipidemic effects of ethanol extracts from two variants of Artemisia princeps Pampanini in obese diabetic mice

Journal of Medicinal Food

Volumn 12, Issue 6, 2009, Pages 1238-1244

  Jung, Un Ju ^a,f   Baek, Nam In ^b   Chung, Hae Gon ^c   Jeong, Tae Sook ^d   Lee, Kyung Tae ^b   Lee, Mi Kyung ^e   Choi, Myung Sook ^a  

^a Kyungpook National University   (South Korea)

^b Kyung Hee University   (South Korea)

^c Ganghwa Agricultural RandD Center   (South Korea)

^d Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^e Sunchon National University   (South Korea)

^f Columbia University ^*  (United States)

Author keywords

Artemisia princeps Pampanini; Lipid regulating enzymes; Type 2 diabetes

Indexed keywords

ALCOHOL; ANTILIPEMIC AGENT; ARTEMISIA PRINCEPS EXTRACT; CHOLESTEROL ACYLTRANSFERASE; FAT DROPLET; FATTY ACID SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LIVER ENZYME; MALATE DEHYDROGENASE (DECARBOXYLATING); PHOSPHATIDATE PHOSPHATASE; PLANT EXTRACT; ROSIGLITAZONE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADIPOCYTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTEMISIA; ARTEMISIA PRINCEPS; ARTICLE; BROWN ADIPOSE TISSUE; CELL SIZE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL ESTERIFICATION; CHOLESTEROL LIVER LEVEL; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DIABETES MELLITUS; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG MECHANISM; ENZYME ASSAY; ENZYME REPRESSION; EPIDIDYMIS; FATTY ACID BLOOD LEVEL; FATTY ACID SYNTHESIS; HISTOPATHOLOGY; HYPOLIPIDEMIC ACTIVITY; LIPID LIVER LEVEL; LIPID METABOLISM; LIPID STORAGE; LIPOGENESIS; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; WHITE ADIPOSE TISSUE;

ANIMALS; ANTILIPEMIC AGENTS; ARTEMISIA; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; ETHANOL; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; PLANT EXTRACTS; RANDOM ALLOCATION; TRIGLYCERIDES;

ANIMALIA; ARTEMISIA PRINCEPS; MUS;

EID: 74349090948     PISSN: 1096620X     EISSN: None     Source Type: Journal    
DOI: 10.1089/jmf.2009.0039     Document Type: Article

References (54)

1. Harris MI, Entmacher PS: Mortality from diabetes. In: Diabetes in America (Harris MI, Hamman RF, ed.). U.S. Government Printing Office, Washington, DC, 1985, pp. 1-48.
2. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-234.
3. Meigs JB, Singer DE, Sullivan LM, Dukes KA, D'Agostino RB, Nathan DM, Wagner EH, Kaplan SH, Greenfield S: Metabolic control and prevalent cardiovascular disease in non-insulindependent diabetes mellitus (NIDDM): the NIDDM Patient Outcome Research Team. Am J Med 1997;102:38-47.
4. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M: Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917-923.
5. Angulo P: Nonalcoholic fatty liver disease. N Engl J Med 2002; 346:1221-1231.
6. Parekh S, Anania FA: Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. Gastroenterology 2007;132:2191-2207.
7. Adams LA, Angulo P, Lindor KD: Nonalcoholic fatty liver disease. CMAJ 2005;172:899-905.
8. Adams LA, Angulo P: Treatment of non-alcoholic fatty liver disease. Postgrad Med J 2006;82:315-322.
9. Spiegelman BM: PPAR-g: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998;47:507-514.
10. Tiikkainen M, Häkkinen AM, Korsheninnikova E, Nyman T, Mäkimattila S, Yki-Järvinen H: Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004;53:2169-2176.
11. Carey DG, Cowin GJ, Galloway GJ, Jones NP, Richards JC, Biswas N, Doddrell DM: Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients. Obes Res 2002;10:1008-1015.
12. Mayerson AB, Hundal RS, Dufour S, LeBon V, Befroy D, Cline GW, Enocksson S, Inzucchi SE, Shulman GI, Petersen KF: The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002;51:797-802.
13. Schwartz S, Raskin P, Fonseca V, Graveline JF: Effect of troglitazone in insulin-treated patients with type II diabetes mellitius. N Engl J Med 1998;338:861-866. (Pubitemid 28135962)
14. Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock JI: A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001;24:1226-1232.
15. Masoudi FA, Wang Y, Inzucchi SE, Setaro JF, Havranek EP, Foody JM, Krumholtz HM: Metformin and thiazolidinedione use in Medicare patients with heart failure. JAMA 2003;290: 81-85.
16. Yeh PH, Chiang W, Chiang MT: Effects of dehulled adlay on plasma glucose and lipid concentrations in streptozotocininduced diabetic rats fed a diet enriched in cholesterol. Int J Vitam Nutr Res 2006;76:299-305.
17. Thielecke F, Boschmann M: The potential role of green tea catechins in the prevention of the metabolic syndrome-a review. Phytochemistry 2009;70:11-24.
18. Zhao QC, Kiyohara H, Yamada H: Anti-complementary neutral polysaccharides from leaves of Artemisia princeps. Phytochemistry 1994;35:73-77.
19. Park EY, Lee KW, Lee HW, Cho YW, Baek NI, Chung HG, Jeong TS, Choi MS, Lee KT: The ethanol extract from Artemisia princeps Pampanini induces p53-mediated G1 phase arrest in A172 human neuroblastoma cells. J Med Food 2008;11:237-245.
20. Kimura Y, Okuda H, Okuda T, Hatano T, Agata I, Arichi S: Studies on the activities of tannins and related compounds from medicinal plants and drugs. VII. Effects of extracts of leaves of Artemisia species and caffeic acid and chlorogenic acid on lipid metabolic injury in rats fed peroxidized oil. Chem Pharm Bull 1985;33:2028-2034.
21. Gilani AH, Janbaz KH: Protective effect of Artemisia scoparia extract against acetaminophen-induced hepatotoxicity. Gen Pharmacol 1993;2:1455-1458.
22. Hoffmann BZ, Herrmann K: Phenolic species: 8. Flavonol glycosides of mugwort (Artemisia vulgaris), tarragon (Artemisia dracunculus L.) and absinthe (Artemisia absinthium L.). Z Lebensm- Unters Forsch 1982;174:211-215.
23. Lee SJ, Chung HY, Lee IK, Yoo ID: Isolation and identification of flavonoids from ethanol extracts of Artemisia vularis and their antioxidant activity. Korean J Food Sci Technol 1999;31:815-822.
24. Kim SC: The study of feed development with wormwood (Artemisia montana Pampan) silage [doctoral thesis]. Gyeongsang National University, Jinju, Republic of Korea, 2003.
25. Ryu SN, Kang SS, Kim JS, Ku BI: Quantitative analysis of eupatilin and jaceosidin in Artemisia herba. Korean J Crop Sci 2004;49:452-456.
26. Kim MJ, Han JM, Jin YY, Baek NI, Bang MH, Chung HG, Choi MS, Lee KT, Sok DE, Jeong TS: In vitro antioxidant and anti-inflammatory activities of jaceosidin from Artemisia princeps Pampanin cv Sajabal. Arch Pharm Res 2008;31:429-437.
27. Han JM, Kim MJ, Baek SH, An S, Jin YY, Chung HG, Baek NI, Choi MS, Lee KT, Jeong TS: Antiatherosclerotic effects of Artemisia princeps Pampanin cv. Sajabal in LDL receptor deficient mice. J Agric Food Chem 2009;57:1267-1274.
28. Jung UJ, Baek NI, Chung HG, Bang MH, Yoo JS, Jeong TS, Lee KT, Kang YJ, Lee MK, Kim HJ, Yeo JY, Choi MS: The antidiabetic effects of ethanol extract from two variants of Artemisia princeps Pampanini in C57BL=KsJ-db=db mice. Food Chem Toxicol 2007;45:2022-2029.
29. Kang YJ, Jung UJ, Lee MK, Kim HJ, Jeon SM, Park YB, Chung HG, Baek NI, Lee KT, Jeong TS, Choi MS: Eupatilin, isolated from Artemisia princeps Pampanini, enhances hepatic glucose metabolism and pancreatic beta-cell function in type 2 diabetic mice. Diabetes Res Clin Pract 2008;82:25-32.
30. Aline M, Charles EL, Marco R, Jeanne M, Odile GN: Determination of the total phenolic, flavonoid and proline contents in Burkina Fasan honey, as well as their radical scavenging activity. Food Chem 2005;91:571-577.
31. Lee JM, Son ES, Oh SS, Han DS: Contents of total flavonoid and biological activities of edible plants. Korean J Diet Culture 2001;16:504-514.
32. American Institute of Nutrition: Report of Ad Hoc Committee on Standards for Nutritional Studies. J Nutr 1980;110:1717-1726.
33. American Institute of Nutrition: Report of the American Institute of Nutrition Ad Hoc Committee on Standards for Nutritional Studies. J Nutr 1977;107:1340-1348.
34. Folch J, Lees M, Sloan-Stanley GH: A simple method for isolation and purification of total lipids from animal tissues. J Biol Chem 1956;226:497-509.
35. Hulcher FH, Oleson WH: Simplified spectrophotometric assay for microsomal 3-hydroxy-3-methylglutaryl CoA reductase by measurement of coenzyme A. J Lipid Res 1973;14:625-631.
36. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254.
37. Carl MN, Lakshmanan MR, Porter JW: Fatty acid synthase from rat liver. Methods Enzymol 1975;35:37-44.
38. Pitkanen E, Pitkanen O, Uotila L: Enzymatic determination of unbound d-mannose in serum. Eur J Clin Chem Clin Biochem 1997;35:761-766.
39. Ochoa S: Malic enzyme: malic enzymes from pigeon and wheat germ. Methods Enzymol 1955;1:323-326.
40. 2+-dependent phosphatidate phosphohydrolase in pulmonary glycerolipid biosynthesis. Biochim Biophys Acta 1984;796:346-372.
41. Shapiro DJ, Nordstrom JL, Mitschelen JJ, Rodwell VW, Schimke RT: Micro assay for 3-hydroxy-3-methylglutaryl-CoA reductase in rat liver and in L-cell fibroblasts. Biochim Biophys Acta 1974;370:369-377.
42. Erickson SK, Schrewsbery MA, Brooks C, Meyer DJ: Rat liver acyl-coenzyme A:cholesterol acyltransferase: its regulation in vivo and some of properties in vitro. J Lipid Res 1980;21:930-941.
43. Muoio DM, Lynis Dohm G: Peripheral metabolic actions of leptin. Best Pract Res Clin Endocrinol Metab 2002;16:653-666.
44. Friedman JM, Halaas JL: Leptin and the regulation of body weight in mammals. Nature 1998;395:763-770.
45. Clement K, Vaisse C, Lahlou N, Cabrol S, Pelloux V, Cassuto D, Gourmelen M, Dina C, Chambaz J, Lacorte JM, Basdevant A, Bougneres P, Lebouc Y, Froguel P, Guy-Grand B: A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature 1998;392:398-401.
46. Mollerr DE: New drug targets for type 2 diabetes and the metabolic syndrome. Nature 2001;414:821-827.
47. McGarry JD: Glucose-fatty acid interactions in health and disease. Am J Clin Nutr 1998;67(3 Suppl):500S-504S.
48. Kudchodkar BJ, Lee JC, Lee SM, DiMarco NM, Lacko AG: Effect on cholesterol homeostasis in diabetic rats. J Lipid Res 1988;29:1272-1287.
49. Windmueller HG, Spaeth AE: De novo synthesis of fatty acid in perfused rat liver as a determinant of plasma lipoprotein production. Arch Biochem Biophys 1967;122:362-369.
50. Memon RA, Grunfeld C, Moser AH, Feingold KR: Fatty acid synthesis in obese insulin resistant diabetic mice. Horm Metab Res 1994;26:85-87.
51. Halminski MA, Marsh JB, Harrison EH: Differential effects of fish oil, safflower oil and palm oil on fatty acid oxidation and glycerolipid synthesis in rat liver. J Nutr 1991;121:1554-1561.
52. Gibbons GF, Burnham FJ: Effect of nutritional state on the utilization of fatty acids for hepatic triacylglycerol synthesis and secretion as very-low-density lipoprotein. Biochem J 1991;275: 87-92.
53. Wang M, Wise SC, Leff T, Su TZ: Troglitazone, an antidiabetic agent, inhibits cholesterol biosynthesis through a mechanism independent of peroxisome proliferators-activated receptorgamma. Diabetes 1999;48:254-260.
54. Trayhurn P, Wusteman MC: Lipogenesis in genetically diabetic (Db=db) mice: developmental changes in brown adipose tissue, white adipose tissue and the liver. Biochim Biophys Acta 1990; 1047:168-174.